Quick Answer
ABBOTT LABORATORIES reported Long-Term Debt of $9.90 billion for fiscal year 2025.
ABBOTT LABORATORIES Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $9.90B | -21.6% |
| 2024 | $12.62B | -7.2% |
| 2023 | $13.60B | -6.4% |
| 2022 | $14.52B | -16.0% |
| 2021 | $17.30B | -6.6% |
| 2020 | $18.53B | +11.2% |
| 2019 | $16.66B | -13.9% |
| 2018 | $19.36B | -28.9% |
| 2017 | $27.21B | +31.6% |
| 2016 | $20.68B | +252.3% |
| 2015 | $5.87B | +73.0% |
| 2014 | $3.39B | +0.1% |
| 2013 | $3.39B | -81.3% |
| 2012 | $18.09B | +50.2% |
| 2011 | $12.04B | -3.9% |
| 2010 | $12.52B | +11.2% |
| 2009 | $11.27B | +29.3% |
| 2008 | $8.71B | -8.2% |
| 2007 | $9.49B | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.60B | -9.6% | -10.3% |
| June 30, 2025 | $12.93B | -1.6% | +1.5% |
| March 31, 2025 | $12.74B | +1.3% | +0.9% |
| December 31, 2024 | $12.62B | -7.2% | -1.6% |
| September 30, 2024 | $12.82B | -11.4% | -2.4% |
| June 30, 2024 | $13.14B | -9.8% | +4.5% |
| March 31, 2024 | $12.58B | -14.0% | -7.5% |
| December 31, 2023 | $13.60B | -6.4% | -6.1% |
- ABBOTT LABORATORIES showed a decrease of -21.6% in Long-Term Debt compared to the prior fiscal year.
- Over the 2007–2025 period, ABBOTT LABORATORIES’s long-term debt has grown by 4.3% (from $9.49 billion to $9.90 billion).
- The most recent figure is from ABBOTT LABORATORIES’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: